Breaking news

Flo Health Secures $200M Investment From General Atlantic, Signaling A New Era In Femtech

by THEFUTURE.TEAM

July 31, 2024

In a landmark move for the femtech industry, Flo Health has secured a $200 million investment from General Atlantic, a leading global growth equity firm. This significant capital infusion marks a pivotal moment for the company, underscoring the growing recognition and potential of technology dedicated to women’s health.

Founded in 2015, Flo Health has swiftly risen to prominence with its innovative mobile application designed to track menstrual cycles, ovulation, and overall reproductive health. The app has garnered over 230 million downloads globally, making it a crucial tool for millions of women seeking to manage their health more effectively. This investment from General Atlantic is poised to propel Flo Health into its next phase of growth, enabling it to expand its product offerings and enhance its technological capabilities.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

General Atlantic’s decision to invest such a substantial sum is indicative of the broader trends within the femtech sector. The femtech market, which includes a range of products and services aimed at improving women’s health, is projected to grow exponentially over the next decade. The increasing awareness of women’s health issues, coupled with advancements in technology, has created a fertile ground for innovation and investment. By backing Flo Health, General Atlantic is not only supporting a single company but also signalling confidence in the sector’s future.

Yaroslava Goncharova, CEO of Flo Health, expressed enthusiasm about the partnership with General Atlantic, stating, “This investment will allow us to accelerate our mission of improving the health and wellbeing of women globally. We are excited to leverage General Atlantic’s expertise and resources to further enhance our product and reach more women around the world.”

Flo Health’s success is rooted in its user-centric approach, leveraging data science and artificial intelligence to provide personalised health insights. The app’s features include symptom tracking, health predictions, and educational content, all designed to empower women with knowledge about their bodies. With the new funding, Flo Health plans to deepen its AI capabilities, enhance its user experience, and expand its educational content, ensuring it remains at the forefront of the femtech industry.

General Atlantic, known for its strategic investments in technology and healthcare, sees Flo Health as a strategic addition to its portfolio. Sandeep Naik, Managing Director and Head of India & Southeast Asia at General Atlantic, highlighted the potential for growth in the femtech space. “Flo Health is at the intersection of healthcare and technology, addressing a significant market need with its innovative solutions. We believe in the company’s vision and are committed to supporting its growth trajectory.”

The $200 million investment also reflects a broader shift in the investment landscape, where gender-specific health solutions are gaining traction among investors. The femtech sector, which has historically been underfunded, is now witnessing increased interest and funding, signalling a positive change in how women’s health is valued and supported.

Flo Health’s journey from a startup to a leading player in femtech exemplifies the transformative potential of technology in healthcare. With General Atlantic’s backing, the company is well-positioned to continue its upward trajectory, driving innovation and improving health outcomes for women worldwide. As Flo Health embarks on this new chapter, the femtech industry will undoubtedly be watching closely, anticipating the strides the company will make in advancing women’s health.

The Future Forbes Realty Global Properties

MammoCheck Secures A €500,000 SEED Grant From The RIF To Advance Toward FDA 510(k) Clearance And EU MDR CE Marking

by News Editor

August 4, 2026

The project is co-funded by the European Union and the Republic of Cyprus under the Cohesion Policy Programme THALIA 2021–2027. Frederick Research Center is participating as a partner organisation, continuing the company’s roots as a spin-out of Frederick University.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

NICOSIA, CYPRUS, July 31, 2026. MammoCheck Ltd, a Cyprus-based medical technology company founded as a spin-out of Frederick University, has secured a €500,000 grant under the Research and Innovation Foundation’s (RIF) SEED programme.

The competitive grant will support the continued development of the company’s adjunctive, research-validated software platform, which combines thermal imaging with artificial intelligence to support breast cancer screening. More specifically, the funding will support the clinical, quality management and regulatory work required as the company advances toward FDA 510(k) clearance in the United States and CE marking under the EU Medical Device Regulation (MDR 2017/745).

The RIF’s SEED programme supports innovative Cypriot start-ups developing internationally competitive products and services. It is co-funded by the European Union through the European Regional Development Fund and the Republic of Cyprus under the Cohesion Policy Programme THALIA 2021–2027.

For MammoCheck, the funding will support completion of its clinical programme, further development of its quality management system in line with ISO 13485, and preparation of the technical documentation and submissions required for the FDA and EU MDR regulatory pathways.

About MammoCheck

MammoCheck is developing a Software as a Medical Device (SaMD) platform that combines a smartphone application, thermal imaging and a proprietary artificial intelligence algorithm to support breast cancer screening.

Founded in 2024 as a spin-out of Frederick University, the company aims to address unequal access to screening. Mammography coverage remains highly uneven worldwide and has been reported as low as 1.7% in some countries, including among many women under the age of 45 who fall outside most national screening programmes.

The platform is being developed for use in primary care and gynaecology settings, as well as for guided home use, with every result reviewed by a clinician. It is intended to complement, rather than replace, established imaging modalities such as mammography and ultrasound.

MammoCheck is currently conducting a clinical study across hospital sites in Cyprus, approved by the Cyprus National Bioethics Committee.

The Role Of Frederick University

Frederick University continues to support the initiative as the institution from which MammoCheck originated. The collaboration also continues through the participation of the Frederick Research Center as a partner organisation in the funded project.

The centre contributes specialised expertise and infrastructure through its Nursing Department and the Mobile Devices Laboratory, focusing on artificial intelligence, smart systems and scientific dissemination. The collaboration strengthens the connection between Cypriot academic research and internationally oriented innovation.

The Frederick team supporting the project includes Dr. Andreas Constantinides, Associate Professor and Director of the Mobile Devices Laboratory, Dr. Evanthia Asimakopoulou, Assistant Professor in the Nursing Department, and Dr. Elena Papoui, Visiting Lecturer in the Nursing Department.

What The Grant Means

The award adds to a period of continued momentum for the company. Alongside its clinical and regulatory progress, MammoCheck is conducting a private investment round to accelerate commercial deployment as it advances toward key regulatory milestones.

The company also holds a Certificate of Innovative Enterprise from the Cyprus Deputy Ministry of Research, Innovation and Digital Policy, allowing eligible investors participating in the funding round to benefit from tax incentives under Cyprus’ innovation investment legislation.

Statements

“Securing €500,000 in competitive, non-dilutive funding is a strong vote of confidence in our vision, our team and our mission. It allows us to focus on what truly matters right now, turning that vision into reality, step by step, as we move steadily toward FDA 510(k) clearance and CE marking under the EU MDR,” said Alexandra Dimitriadou, Co-Founder and CEO of MammoCheck.

Athina Grigoriou, Co-Founder and CRO, added: “Our clinical programme is at the heart of this project. This support strengthens the study we are conducting across hospital sites in Cyprus and the evidence base behind every step of our regulatory pathway.”

Marios Pafitis, Co-Founder and CTO, said: “Working alongside the Frederick Research Center brings academic rigour to our engineering. This grant helps us take the technology from promising research toward a rigorously engineered and clinically validated product.”

The MammoCheck co-founding team, Alexandra Dimitriadou, Marios Pafitis and Athina Grigoriou, was named to the Forbes 30 Under 30 Greece list in 2026.

The MAMMOCHECK project (SEED/0525(B)/0102) is implemented under the Cohesion Policy Programme THALIA 2021–2027 and is co-funded by the European Union through the European Regional Development Fund and the Republic of Cyprus via the Research and Innovation Foundation.